Cyclo Therapeutics (Nasdaq:CYTH) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CYTH Overzicht aandelen

CYTH fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 71.31% per jaar groeien

Risicoanalyse

Negatief eigen vermogen

Volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( $23M )

+ 2 meer risico's

Cyclo Therapeutics, Inc. Concurrenten

Zeo ScientifiX

OTCPK:ZEOX

US$15.5m

HCW Biologics

NasdaqGM:HCWB

US$20.4m

Aprea Therapeutics

NasdaqCM:APRE

US$14.9m

OpGen

OTCPK:OPGN

US$16.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cyclo Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$0.77
52 Week Hoogtepunt	US$2.12
52 Week Laag	US$0.59
Bèta	-0.39
11 maand verandering	2.98%
3 maanden verandering	-36.89%
1 Jaar Verandering	-36.85%
33 jaar verandering	-88.14%
5 jaar verandering	-95.84%
Verandering sinds IPO	-99.62%

Recent nieuws en updates

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Rendement voor aandeelhouders

	CYTH	US Biotechs	US Markt
7D	14.9%	-0.2%	-0.4%
1Y	-36.8%	22.1%	34.1%

Rendement versus industrie: CYTH presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 21.7 % opleverde.

Rendement versus markt: CYTH presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 33.4 % opleverde.

Prijsvolatiliteit

Is CYTH's price volatile compared to industry and market?
CYTH volatility
CYTH Average Weekly Movement	12.1%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van CYTH is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van CYTH is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1990	8	N. Fine	cyclotherapeutics.com

Cyclo Therapeutics, Inc, een biotechnologiebedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van op cyclodextrine gebaseerde producten voor de behandeling van neurodegeneratieve ziekten. Het belangrijkste kandidaat-geneesmiddel van het bedrijf is Trappsol Cyclo (hydroxypropylbètacyclodextrine), een weesgeneesmiddel dat zich in Fase III van de klinische tests bevindt voor de behandeling van de ziekte van Niemann-Pick Type C en in Fase IIb van de klinische tests voor de behandeling van de ziekte van Alzheimer. Het bedrijf verkoopt ook cyclodextrinen en aanverwante producten aan de farmaceutische, voedings- en andere industrieën, voornamelijk voor gebruik in diagnostica en speciale geneesmiddelen.

Cyclo Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Cyclo Therapeutics zich tot de beurswaarde?
CYTH fundamentele statistieken
Marktkapitalisatie	US$22.64m
Inkomsten(TTM)	-US$20.74m
Inkomsten(TTM)	US$1.13m

19.5x

P/S-verhouding

-1.1x

Koers/Winstverhouding

Is CYTH overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CYTH resultatenrekening (TTM)
Inkomsten	US$1.13m
Kosten van inkomsten	US$95.57k
Brutowinst	US$1.04m
Overige uitgaven	US$21.77m
Inkomsten	-US$20.74m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.72
Brutomarge	91.56%
Nettowinstmarge	-1,831.29%
Schuld/Eigen Vermogen Verhouding	-52.9%

Hoe presteerde CYTH op de lange termijn?

Bekijk historische prestaties en vergelijking

CYTH Overzicht aandelen

Beloningen

Risicoanalyse

Cyclo Therapeutics, Inc. Concurrenten

OTCPK:ZEOX

US$15.5m

NasdaqGM:HCWB

US$20.4m

NasdaqCM:APRE

US$14.9m

OTCPK:OPGN

US$16.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Recent updates

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo

Cyclo therapeutics to join Russell 2000 Index

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics Provides Business Update